Latest News From Lumira Ventures

Cardiac Dimensions Announces Positive Late-Breaking Results for Blinded Clinical Trial of Minimally Invasive Heart Failure Treatment

Ahmed Khan Cardiac Dimensions, Portfolio News

In Randomized Blinded Study, the Carillon Mitral Contour System Catheter-Based Treatment Meets Endpoint for Reduction in Regurgitant Volume KIRKLAND, Wash.- Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular …

G1 Therapeutics to Report Myelopreservation Data from Randomized Phase 2 Trial of Trilaciclib/Chemotherapy/Tecentriq® in Small Cell Lung Cancer in Fourth Quarter 2018

Ahmed Khan G1 Therapeutics, Portfolio News

G1 Therapeutics (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it is expediting analyses of myelopreservation data from its randomized Phase 2 trial of trilaciclib in combination with chemotherapy and Tecentriq® (atezolizumab) in first-line small cell lung cancer (SCLC). Myelopreservation results …